Prostate cancer therapy could cause cataracts

Article

Androgen deprivation therapy (ADT) used for prostate cancer treatment could contribute towards the development of cataracts.

An investigation by Dr Jennifer Beebe-Dimmer et al, Karmanos Cancer Institute in Detroit, Michigan, USA, has shown that androgen deprivation therapy (ADT) used for prostate cancer treatment could contribute towards the development of cataracts.

ADT has already been proven to increase the chances of developing diabetes and other heart problems.

The study included 66000 prostate cancer patients aged 66 or older from a US cancer registry. Almost half of the patients were treated by ADT within six months of diagnosis. For every 1000 patients studied, 111 cataracts were diagnosed.

The men treated with ADT had an average of 9% increased risk of developing cataracts. This rose by about 26% for the men who had their testicles removed.

In conclusion, it was estimated that 5% of cataract cases in patients with prostate cancer could be attributed to ADT.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.